The FDA approved the company's sleep apnea monitoring system, Morpheus Ox, for home use.
WideMed Ltd. (TASE:WDMD) has obtained US Food and Drug Administration (FDA) approval for its sleep apnea monitoring system, Morpheus Ox, for home use. With the FDA certification, the company will begin home marketing of the system.
Morpheus Ox uses blood oxygen signals by standard oxymeters to monitor sleep apnea and related cardiology variables. The system can be used at hospitals and at home.
Widemed's share price rose 24.6% by early afternoon to NIS 0.756, giving a market cap of NIS 12 million.
Published by Globes [online], Israel business news - www.globes-online.com - on September 4, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011